Tumor Biology

, Volume 36, Issue 6, pp 4591–4596 | Cite as

XRCC1 polymorphisms associated with survival among Chinese bladder cancer patients receiving epirubicin and mitomycin C

  • Xiaheng Deng
  • Xiaolei Zhang
  • Yidong Cheng
  • Xiao Yang
  • Ruizhe Zhao
  • Xuzhong Liu
  • Xiao Li
  • Chao Qin
  • Qiang Lu
  • Changjun Yin
Research Article
  • 148 Downloads

Abstract

The association between DNA repair gene polymorphisms and bladder cancer risk has been widely studied. However, only few studies have examined the correlation between bladder cancer and instillation agent sensitivity. The aim of this study was to examine the association between polymorphisms of DNA repair genes, namely X-ray repair cross-complementing group I (XRCC1) rs2854509 and rs3213255, and bladder cancer recurrence risk. We recruited 244 patients (130 treated with epirubicin and 114 treated with mitomycin C). Genomic DNA was used to examine the XRCC1 rs2854509 and rs3213255 genotypes by Taqman PCR analysis. Combination analysis of XRCC1 rs2854509 and rs3213255 and examination of XRCC1 diplotypes were performed to reveal possible correlations. The rs2854509 CC and rs3213255 TT genotypes conferred shorter survival times than the rs2854509 AC/AA and rs3213255 CC/CT genotypes in patients treated with epirubicin, but not in those treated with mitomycin C (MMC) in adjusted models [hazard ratio (HR) = 0.23, 95 % confidence interval (CI) = 0.10–0.53 for rs2854509 AC + AA compared with CC; HR = 0.17, 95 % CI = 0.06–0.46 for rs3213255 CC + CT compared with TT]. Combination analysis showed significantly increased recurrence-free survival (RFS) among patients simultaneously carrying the rs2854509 AC/AA and rs3213255 CC/CT genotypes with an HR of 0.15 (95 % CI = 0.05–0.45) compared to those carrying other genotypes. Diplotype analysis demonstrated that the A-C/C-T diplotype is associated with a lower risk of recurrence compared with the common wild C-T/C-T diplotype (HR = 0.17, 95 % CI = 0.06–0.51). Our results suggest that the rs2854509 CC and rs3213255 TT genotypes confer higher sensitivity to epirubicin instillation. Moreover, the A-C/C-T diplotype presents significantly lower recurrence risk than other diplotypes.

Keywords

Bladder cancer XRCC1 Epirubicin Mitomycin C Chemosensitive 

Notes

Acknowledgments

This work was funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), the Program for Development of Innovative Research Team in the First Affiliated Hospital of Nanjing Medical University, Provincial Initiative Program for Excellency Disciplines of Jiangsu Province and the National Natural Science Foundation of China (grant numbers 81171963 and 81201571).

Conflicts of interest

None

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA 2014;64:9–29.Google Scholar
  2. 2.
    Rubben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G. Natural history and treatment of low and high risk superficial bladder tumors. J Urol. 1988;139:283–5.PubMedGoogle Scholar
  3. 3.
    Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239–49.CrossRefPubMedGoogle Scholar
  4. 4.
    Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R, et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer. 2009;45:931–91.CrossRefPubMedGoogle Scholar
  5. 5.
    Alexandroff AB, Nicholson S, Patel PM, Jackson AM. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer. Immunotherapy. 2010;2:551–60.CrossRefPubMedGoogle Scholar
  6. 6.
    Ali-el-Dein B, el-Baz M, Aly AN, Shamaa S, Ashamallah A. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. J Urol. 1997;158:68–73. discussion 73-64.CrossRefPubMedGoogle Scholar
  7. 7.
    Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171:2186–90. quiz 2435.CrossRefPubMedGoogle Scholar
  8. 8.
    Przybylowska-Sygut K, Stanczyk M, Kusinska R, Kordek R, Majsterek I. Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among polish women with breast cancer. Clin Breast Cancer. 2013;13:61–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, Zuo ZF, Ashok TD, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis. 2000;21:965–71.CrossRefPubMedGoogle Scholar
  10. 10.
    Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S, Selvaggi G, et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res. 2007;13:2876–81.CrossRefPubMedGoogle Scholar
  11. 11.
    Tengstrom M, Mannermaa A, Kosma VM, Hirvonen A, Kataja V. XRCC1 rs25487 polymorphism predicts the survival of patients after postoperative radiotherapy and adjuvant chemotherapy for breast cancer. Anticancer Res. 2014;34:3031–7.PubMedGoogle Scholar
  12. 12.
    Sacerdote C, Guarrera S, Ricceri F, Pardini B, Polidoro S, Allione A, et al. Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy. Int J Cancer. 2013;133:2004–9.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hung RJ, Hall J, Brennan P, Boffetta P. Genetic polymorphisms in the base excision repair pathway and cancer risk: a huge review. Am J Epidemiol. 2005;162:925–42.CrossRefPubMedGoogle Scholar
  14. 14.
    Arizono K, Osada Y, Kuroda Y. DNA repair gene hOGG1 codon 326 and XRCC1 codon 399 polymorphisms and bladder cancer risk in a Japanese population. Jpn J Clin Oncol. 2008;38:186–91.CrossRefPubMedGoogle Scholar
  15. 15.
    Sakano S, Wada T, Matsumoto H, Sugiyama S, Inoue R, Eguchi S, et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer. 2006;95:561–70.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Sanyal S, De Verdier PJ, Steineck G, Larsson P, Onelov E, Hemminki K, et al. Polymorphisms in XPD, XPC and the risk of death in patients with urinary bladder neoplasms. Acta Oncol. 2007;46:31–41.CrossRefPubMedGoogle Scholar
  17. 17.
    Li C, Hu Z, Lu J, Liu Z, Wang LE, El-Naggar AK, et al. Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck. Cancer. 2007;110:867–75.CrossRefPubMedGoogle Scholar
  18. 18.
    Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco I, et al. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res. 2006;12:2101–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Cullinane C, Cutts SM, Panousis C, Phillips DR. Interstrand cross-linking by adriamycin in nuclear and mitochondrial DNA of MCF-7 cells. Nucleic Acids Res. 2000;28:1019–25.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Memisoglu A, Samson L. Base excision repair in yeast and mammals. Mutat Res. 2000;451:39–51.CrossRefPubMedGoogle Scholar
  21. 21.
    Watchko JF, Lin Z, Clark RH, Kelleher AS, Walker MW, Spitzer AR. Pediatrix Hyperbilirubinemia Study G. Complex multifactorial nature of significant hyperbilirubinemia in neonates. Pediatrics. 2009;124:e868–77.CrossRefPubMedGoogle Scholar
  22. 22.
    Kaplan M, Renbaum P, Levy-Lahad E, Hammerman C, Lahad A, Beutler E. Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency: a dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia. Proc Natl Acad Sci U S A. 1997;94:12128–32.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Lu Q, Cui Y, Wu R. A multilocus likelihood approach to joint modeling of linkage, parental diplotype and gene order in a full-sib family. BMC Genet. 2004;5:20.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Xiaheng Deng
    • 1
  • Xiaolei Zhang
    • 1
  • Yidong Cheng
    • 1
  • Xiao Yang
    • 1
  • Ruizhe Zhao
    • 1
  • Xuzhong Liu
    • 1
  • Xiao Li
    • 1
  • Chao Qin
    • 1
  • Qiang Lu
    • 1
  • Changjun Yin
    • 1
  1. 1.Department of UrologyThe First Affiliated Hospital of Nanjing Medical UniversityNanjingChina

Personalised recommendations